Description
Rivaroxaban is an orally bioavailable oxazolidone derivative that acts as an antithrombotic/anticoagulant, reversibly inhibiting factor Xa. Rivaroxaban directly binds to the S1 and S4 pockets of factor Xa and inhibits both free and clot-bound forms. In vitro models indicate that rivaroxaban may also exert inhibitory effects during the early stages of bone formation, as it inhibits hormone-stimulated modulation of ER and 1-OHase expression as well as DNA synthesis, creatine kinase activity, and alkaline phosphatase activity.
References
Kreutz R. Pharmacokinetics and Pharmacodynamics of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor. Curr Clin Pharmacol. 2013 Nov 11. [Epub ahead of print]. PMID: 24218999.
Somjen D, Katzburg S, Gigi R, et al. Rivaroxaban, a direct inhibitor of the coagulation factor Xa interferes with hormonal-induced physiological modulations in human female osteoblastic cell line SaSO2. J Steroid Biochem Mol Biol. 2013 May;135:67-70. PMID: 23333933
Gigi R, Salai M, Dolkart O, et al. The effects of direct factor Xa inhibitor (Rivaroxaban) on the human osteoblastic cell line SaOS2. Connect Tissue Res. 2012;53(6):446-50. PMID: 22800431.
Samama MM. The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants. Thromb Res. 2011 Jun;127(6):497-504. PMID: 20888031.
